FLT3LG and metastatic melanoma: A randomized clinical trial that conducted FLT3L pre-treatment enhancement of responses to the DC vaccine in combination with the TLR3 agonist for metastatic melanoma found that the addition of FLT3L increased peripheral cDC1, cDC2, and plasmacytoid DCs.